SEC Form 4 · accession 0001209191-15-069484
TETRAPHASE PHARMACEUTICALS INC · TTPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Guy Macdonald
Officer — President and Chief Executive · Director
Period of report
Sep 1, 2015
Accepted (ET)
Sep 3, 2015 · 5:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001373707
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 1, 2015 | M | 10,000 | $7.94 | A | 62,000 | D | |
| Common StockF1,F2 | Sep 1, 2015 | S | 10,000 | $41.57 | D | 52,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1,F3 | $7.94 | Sep 1, 2015 | M | 10,000 | D | — | May 14, 2023 | Common Stock | 10,000 | 180,000 | D |
Explanation of responses
- F1The exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2014.
- F2The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $40.51 to $43.34 per share. The reporting person herby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission,the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F3Vests as to 25% of the original number of shares granted on 5/15/2014 and further vests as to an additional 6.25% of the original number of shares granted at the end of each successive three-month period thereafter until 5/15/2017.